rawfin.tv
Artiva Biotherapeutics CEO Sells Shares Under 10b5-1 Plan
MarketsstocksAI Generated

Artiva Biotherapeutics CEO Sells Shares Under 10b5-1 Plan

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Fred Aslan, CEO of Artiva Biotherapeutics (NASDAQ: ARTV), sold 23,429 shares of the company's common stock. The sale was executed under a pre-arranged 10b5-1 trading plan.

ARTVInsider TradingBiotechnologyExecutive Transactions

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks